20 January 2020
: Case report
T Cell Primary Effusion Lymphoma in an HIV-Negative Man with Liver Cirrhosis
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare disease, Clinical situation which can not be reproduced for ethical reasons
Jacqueline Kropf1ABDEF, Mina Gerges1BCE, Ariel Perez Perez1ABDE, Austin Ellis1CDE, Mevin Mathew2ABF, Kwabena Ayesu1BCE, Li Ge3CDE, Steve J. Carlan4DEF*DOI: 10.12659/AJCR.919032
Am J Case Rep 2020; 21:e919032
Abstract
BACKGROUND: Primary effusion lymphoma (PEL) is a rare and aggressive non-Hodgkin lymphoma (NHL) that is responsible for 1% of all lymphomas not related to human immunodeficiency virus (HIV). PEL is characterized by human herpesvirus-8 (HHV-8) positivity in the absence of overt tumor burden that does not exhibit typical B cell or T cell immunophenotype characteristics. The exact mechanism of development is unknown, but it is hypothesized to develop from post-germinal B cell origin. Although it is most common in HIV patients, other immunocompromising comorbidities can be seen in conjunction with PEL, including liver cirrhosis.
CASE REPORT: We present the case of a 73-year-old HIV-seronegative man with alcohol-induced liver cirrhosis who was found to have T cell PEL of the pleural space diagnosed by thoracentesis.
CONCLUSIONS: Little is known regarding oncogenesis of T cell PEL, and few studies exist regarding appropriate treatment regimens for PEL as a whole, prompting need for further investigation and discussion to improve survival rates. Even in the absence of active HIV infection, PEL should be considered as a potential cause of pleural effusion in cirrhotic patients in order to prompt earlier treatment for the best chance of survival.
Keywords: Liver Cirrhosis, Alcoholic, Lymphoma, Primary Effusion, Pleural Effusion, Malignant, HIV Seronegativity, Immunocompromised Host, Liver Cirrhosis, Lymphoma, T-Cell, thoracentesis
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946589
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947316
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947693
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947911
Most Viewed Current Articles
21 Jun 2024 : Case report
100,250
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
53,680
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
36,071
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
07 Jul 2023 : Case report
24,897
DOI :10.12659/AJCR.940200
Am J Case Rep 2023; 24:e940200